Onychomycosis is a fungal infection of the nail resulting in discoloration, thickening, and separation from the nail bed. Pediatric onychomycosis has a reported incidence of 0.4% to 2.6%.1 Topical antifungal therapy has been shown to have some efficacy in children compared with adults; however, when the infection involves the nail matrix, systemic therapy is often indicated.2 Terbinafine is the systemic antifungal of choice, with cure rates as high as 80%.3 Though terbinafine is well tolerated, hepatotoxic effects have been reported in adults.4 There are fewer risk factors for liver injury in children and consensus regarding laboratory surveillance during therapy has not been reached, with physician preference varying widely. The aim of our study was to investigate the prevalence of laboratory monitoring and laboratory abnormalities during systemic terbinafine therapy in pediatric patients with onychomycosis.
Patel D, Castelo-Soccio LA, Rubin AI, Streicher JL. Laboratory Monitoring During Systemic Terbinafine Therapy for Pediatric Onychomycosis. JAMA Dermatol. 2017;153(12):1326–1327. doi:10.1001/jamadermatol.2017.4483
Customize your JAMA Network experience by selecting one or more topics from the list below.